Education
About Us
Working with TipRanks
Follow Us
Vera Therapeutics (VERA)
NASDAQ:VERA
VERA Stock Chart & Stats
$25.22
-$0.18(-0.43%)
At close: 4:00 PM EST
$25.22
-$0.18(-0.43%)
Day’s Range― - ―
52-Week Range$18.53 - $51.61
Previous CloseN/A
Volume142.65K
Average Volume (3M)1.47M
Market Cap
$1.54B
Enterprise Value$1.02B
Total Cash (Recent Filing)$497.39M
Total Debt (Recent Filing)$77.22M
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Mar 19, 2026EPS Estimate
-1.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.26
Shares Outstanding63,823,666
10 Day Avg. Volume1,120,971
30 Day Avg. Volume1,474,393
Financial Highlights & Ratios
PEG Ratio-0.69
Price to Book (P/B)4.05
Price to Sales (P/S)0.00
P/FCF Ratio-17.25
Enterprise Value/Market Cap0.67
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.82K
Enterprise Value/Ebitda-3.99
Forecast
1Y Price Target
$67.50Price Target Upside167.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial LaunchVera Therapeutics is on track to submit a BLA for atacicept in IgAN with a potential commercial launch in 2026, and expects Priority Review due to its Breakthrough Therapy Designation.
Market PotentialAtacicept for IgAN is the largest single product driver with blockbuster potential and anticipated conditional marketing approval, representing a $15bn peak market where biologics command high pricing.
Safety ProfileAtacicept continues to be well-tolerated, with a similar rate of infections and a lower proportion of serious and adverse events leading to drug discontinuation.
Bears Say
Competitive RiskThe biggest risk to the Buy rating is the evolving clinical profiles of competitor BAFF/APRIL drugs being developed by well-capitalized sponsors.
Diagnostic ChallengesThere is no reliable serum or urine biomarker for diagnosing IgAN, which requires a kidney biopsy for accurate diagnosis.
Vera Therapeutics News
VERA FAQ
What was Vera Therapeutics’s price range in the past 12 months?
Vera Therapeutics lowest stock price was $18.53 and its highest was $51.61 in the past 12 months.
What is Vera Therapeutics’s market cap?
Vera Therapeutics’s market cap is $1.54B.
When is Vera Therapeutics’s upcoming earnings report date?
Vera Therapeutics’s upcoming earnings report date is Mar 19, 2026 which is in 132 days.
How were Vera Therapeutics’s earnings last quarter?
Vera Therapeutics released its earnings results on Nov 05, 2025. The company reported -$1.26 earnings per share for the quarter, missing the consensus estimate of -$1.162 by -$0.098.
Is Vera Therapeutics overvalued?
According to Wall Street analysts Vera Therapeutics’s price is currently Undervalued.
Does Vera Therapeutics pay dividends?
Vera Therapeutics does not currently pay dividends.
What is Vera Therapeutics’s EPS estimate?
Vera Therapeutics’s EPS estimate is -1.23.
How many shares outstanding does Vera Therapeutics have?
Vera Therapeutics has 63,823,666 shares outstanding.
What happened to Vera Therapeutics’s price movement after its last earnings report?
Vera Therapeutics reported an EPS of -$1.26 in its last earnings report, missing expectations of -$1.162. Following the earnings report the stock price went down -1.027%.
Which hedge fund is a major shareholder of Vera Therapeutics?
Currently, no hedge funds are holding shares in VERA
Vera Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$67.50 (167.64% Upside)
$67.50 (167.64% Upside)
Hedge Fund Trend
Increased
By 3.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.2%
Last 30 Days >0.1%
Last 30 Days >0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.70%
12-Months-Change
Fundamentals
Return on Equity
-73.25%
Trailing 12-Months
Asset Growth
45.62%
Trailing 12-Months
Company Description
Vera Therapeutics
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
VERA Stock 12 Month Forecast
Average Price Target
$67.50
▲(167.64% Upside)
Technical Analysis
Viridian Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Janux Therapeutics Inc
―
Biohaven Ltd.
―
Ownership Overview
13.61% Insiders
15.97% Mutual Funds
0.10% Other Institutional Investors
56.63% Public Companies and Individual Investors